Table 1.

Clinical Characteristics of the Children with Acute Lymphoblastic Leukemia 12 Months After the Initiation of Therapy

Clinical Characteristics	N=155 *
Demographic Data
Male, N (%)	91 (59)
Age at 12 months (years), median (min, max)	6.4 (2.2, 18.0)
Bone Age at 12 months (years), median (min, max)	5.8 (2.0, 18.5)
Diagnosis, N (%)
Pre-B-cell acute lymphoblastic leukemia	141 (91)
T-cell acute lymphoblastic leukemia	14 (9)
Leukemia protocol, N (%)
Dana Farber	33 (21)
Children’s Oncology Group	122 (79)
Leukemia risk category, N (%)
Standard Risk	96/153 (63)
High Risk	57/153 (37)
Anthropometry, mean (SD)
Δ Height Z-score from baseline to 12 months	−0.4 (0.5)
Δ Weight Z-score from baseline to 12 months	0.1 (0.7)
Δ BMI** Z-score from baseline to 12 months	0.5 (1.0)
Lumbar Spine Bone Mineral Density, mean (SD)
LS BMD Z-score at baseline	−1.2 (1.3)
Δ LS BMD Z-score from baseline to 12 months	0.1 (0.9)
Vitamin D and Calcium Intake
Average daily vitamin D intake***, N (%)
< 50 %	25/123 (20)
50 – <100 %	63/123 (51)
>= 100%	35/123 (29)
Average daily calcium intake***, N (%)
< 50 %	5/124 (4)
50 – <100 %	11/124 (9)
>= 100%	108/124 (87)

^*For data expressed as percentages, the denominator is 155 children unless otherwise specified

^**BMI = Body mass index

^***Combined dietary plus supplemental intake, expressed as the % of the Dietary Reference Intake for age